<DOC>
	<DOC>NCT01121198</DOC>
	<brief_summary>This study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ASP1941 in healthy adult male subjects.</brief_summary>
	<brief_title>A Study to Assess Safety and Tolerability of ASP1941 After Single and Repeated Administration in Healthy Subjects</brief_title>
	<detailed_description>This study consists of two parts. In part-1, a single oral dose of ASP1941 or placebo is administered to healthy adult male subjects to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics in healthy adult males. In part-2, ASP1941 or placebo are is administered by a multiple dose regimen.</detailed_description>
	<criteria>Body weight: 50.0 kg ≤ weight &lt; 85.0 kg Body mass index:17.6 ≤ BMI &lt; 26.4 Those who provided written informed consent themselves Medical history of Hepatic disease, heart disease, respiratory disease, gastrointestinal disease, renal disease, cerebrovascular disease, malignant tumor or drug allergy Those whose blood pressure, pulse rate, body temperature or 12lead ECG are in the abnormal range Those whose labtest results are in the abnormal range Those who received medical treatment within 14 days prior to the study Those who attended another clinical study or a postmarketing clinical trial within 120 days before the study Those who have received ASP1941 before Those who have donated at least 400ml of whole blood within 90 days before the study, at least 200ml 30 days before the study or blood component within 14 days before the study Those within a fasting plasma glucose level of &lt; 70mg/dL or 110 mg/dL or with an HbA1C. 5.8%</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Food effect</keyword>
</DOC>